T. Rowe Price Investment Management, Inc. Arcellx, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Arcellx, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 705,922 shares of ACLX stock, worth $49.9 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
705,922
Previous 944,638
25.27%
Holding current value
$49.9 Million
Previous $78.9 Million
31.37%
% of portfolio
0.03%
Previous 0.05%
Shares
6 transactions
Others Institutions Holding ACLX
# of Institutions
224Shares Held
45.1MCall Options Held
434KPut Options Held
433K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$309 Million12.7% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$265 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$249 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$246 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$236 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.1B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...